Avtor/Urednik		Strohmaier, Jana; Wuest, Stefan; Dernovšek, Mojca Z; Kozel, Dejan
Naslov		Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR
Tip		članek
Vir		World J Biol Psychiatr
Vol. in št.		Letnik 12, št. 7
Leto izdaje		2011
Obseg		str. 528-38
Jezik		eng
Abstrakt		Objectives: Sexual dysfunction (SD) is a frequently reported side-effect of antidepressant treatment, particularly of selective serotonin reuptake inhibitors (SSRIs). In the multicentre clinical and pharmacogenetic GENDEP study (Genome-based Therapeutic Drugs for Depression), the effect of the serotonin transporter gene promoter polymorphism 5-HTTLPR on sexual function was investigated during treatment with escitalopram (SSRI) and nortriptyline (tricyclic antidepressant). Methods: A total of 494 subjects with an episode of DSM-IV major depression were randomly assigned to treatment with escitalopram or nortriptyline. Over 12 weeks, depressive symptoms and SD were measured weekly with the Montgomery-Asberg Depression Rating Scale, the Antidepressant Side-Effect Checklist, the UKU Side Effect Rating Scale, and the Sexual Functioning Questionnaire. Results: The incidence of reported SD after 12 weeks of treatment was relatively low, and did not differ significantly between antidepressants (14.9% escitalopram, 19.7% nortriptyline). There was no significant interaction between the 5-HTTLPR and antidepressant on SD. Improvement in depressive symptoms and younger age were both associated with lower SD. The effect of age on SD may have been moderated by the 5-HTTLPR. Conclusion: In GENDEP, rates of reported SD during treatment were lower than those described in previous reports. There was no apparent effect of the 5-HTTLPR on the observed decline in SD.
Deskriptorji		DEPRESSIVE DISORDER ANTIDEPRESSIVE AGENTS SEROTONIN UPTAKE INHIBITORS NORTRIPTYLINE PHARMACOGENETICS POLYMORPHISM (GENETICS) GENOTYPE EDETIC ACID POLYMERASE CHAIN REACTION SEX FACTORS MULTICENTER STUDIES